Last updated on March 2019

A 12-week randomized, double-blind, parallel-group, placebo-controlled study to determine the efficacy and safety of biphasic remogliflozin etabonate when administered to subjects with type 2 diabetes mellitus.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetes Mellitus | Type 2
  • Age: 18 Years
  • Gender: Male or Female

Inclusion Criteria:

  • T2DM with HbA1c 7.0-10.5% using no ADMs or metformin alone.

Exclusion Criteria:

  • eGFR less than 30
  • 2 or more UTI's in past 12 months
  • Malignancy within past 3 years
  • Working night shift and sleeping during the day

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.